The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Endo International Plc (NASDAQ: ENDP) securities between August 8, 2017 and June 10, 2020.
According to the Endo lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Endo’s and/or its subsidiaries’ contributions to the opioid crisis (including, but not limited to, their opioid products’ disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Endo you have until August 18, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.